Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver

Human Gene Therapy

Volumn 19, Issue 10, 2008, Pages 1039-1049

  Kopitz, Charlotte ^a   Gerg, Michael ^a   Gansbacher, Bernd ^a   Krüger, Achim ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C; CYSTEINE PROTEINASE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; LIVER METASTASIS; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR CELL; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CYSTATIN C; CYSTEINE ENDOPEPTIDASES; FIBROSARCOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

MURINAE; MUS;

EID: 54949087549     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2008.078     Document Type: Article

References (39)

1. Abrahamson, M., Alvarez-Fernandez, M., and Nathanson, C.M. (2003). Cystatins. Biochem. Soc. Symp. 70, 179-199.
2. Arlt, M., Kopitz, C., Pennington, C., Watson, K.L., Krell, H.W., Bode, W., Gansbacher, B., Khokha, R., Edwards, D.R., and Krüger, A. (2002). Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res. 62, 5543-5550.
3. Baker, A.H., Edwards, D.R., and Murphy, G. (2002). Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J. Cell Sci. 115, 3719-3727.
4. Barrett, A.J., Kembhavi, A.A., Brown, M.A., Kirschke, H., Knight, C.G., Tamai, M., and Hanada, K. (1982). L-trans-Epoxysuccinyl- leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem. J. 201, 189-198.
5. Brand, K. (2002). Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr. Gene Ther. 2, 255-271.
6. Chirco, R., Liu, X.W., Jung, K.K., and Kim, H.R. (2006). Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 25, 99-113.
7. Coussens, L.M., Fingleton, B., and Matrisian, L.M. (2002). Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295, 2387-2392.
8. Declerck, Y.A., Imren, S., Montgomery, A.M., Mueller, B.M., Reisfeld, R.A., and Laug, W.E. (1997). Proteases and protease inhibitors in tumor progression. Adv. Exp. Med. Biol. 425, 89-97.
9. Della Porta, P., Soeltl, R., Krell, H.W., Collins, K., O'Donoghue, M., Schmitt, M., and Krüger, A. (1999). Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo. Anticancer Res. 19, 3809-3816.
10. Deryugina, E.I., and Quigley, J.P. (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25, 9-34.
11. Duffy, M.J. (2004). The urokinase plasminogen activator system: Role in malignancy. Curr. Pharm. Des. 10, 39-49.
12. Egeblad, M., and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
13. Gocheva, V., and Joyce, J.A. (2007). Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6, 60-64.
14. Gupta, G.P., and Massague, J. (2006). Cancer metastasis: Building a framework. Cell 127, 679-695.
15. Hitt, M., Bett, A.J., Addison, C.L., Prevec, L., and Graham, F.L. (1995). Techniques for human adenovirus vector construction and characterization. In Viral Gene Techniques. K.W. Adolph, ed. (Academic Press, San Diego, CA) pp. 13-30.
16. Jiang, Y., Goldberg, I.D., and Shi, Y.E. (2002). Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21, 2245-2252.
17. Jones, N., and Shenk, T. (1978). Isolation of deletion and substitution mutants of adenovirus type 5. Cell 13, 181-188.
18. Kaplan, R.N., Riba, R.D., Zacharoulis, S., Bramley, A.H., Vincent, L., Costa, C., Macdonald, D.D., Jin, D.K., Shido, K., Kerns, S.A., Zhu, Z., Hicklin, D., Wu, Y., Port, J.L., Altorki, N., Port, E.R., Ruggero, D., Shmelkov, S.V., Jensen, K.K., Rafii, S., and Lyden, D. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827.
19. Kaplan, R.N., Rafii, S., and Lyden, D. (2006). Preparing the "soil": The premetastatic niche. Cancer Res. 66, 11089-11093.
20. Kopitz, C., Anton, M., Gansbacher, B., and Krüger, A. (2005). Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host. Cancer Res. 65, 8608-8612.
21. Kopitz, C., Gerg, M., Bandapalli, O.R., Ister, D., Pennington, C.J., Hauser, S., Flechsig, C., Krell, H.W., Antolovic, D., Brew, K., Nagase, H., Stangl, M., von Weyhern, C.W., Brucher, B.L., Brand, K., Coussens, L.M., Edwards, D.R., and Krüger, A. (2007). Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res. 67, 8615-8623.
22. Kos, J., Werle, B., Lah, T., and Brunner, N. (2000). Cysteine proteinases and their inhibitors in extracellular fluids: Markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers 15, 84-89.
23. Koshariya, M., Jagad, R.B., Kawamoto, J., Papastratis, P., Kefalourous, H., Porfiris, T., Tzouma, C., and Lygidakis, N.J. (2007). An update and our experience with metastatic liver disease. Hepatogastroenterology 54, 2232-2239.
24. Krüger, A., Schirrmacher, V., and Khokha, R. (1998). The bacterial lacZ gene: An important tool for metastasis research and evaluation of new cancer therapies. Cancer Metastasis Rev. 17, 285-294.
25. Krüger, A., Soeltl, R., Sopov, I., Kopitz, C., Arlt, M., Magdolen, V., Harbeck, N., Gansbacher, B., and Schmitt, M. (2001). Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res. 61, 1272-1275.
26. Krüger, A., Arlt, M.J., Gerg, M., Kopitz, C., Bernardo, M.M., Chang, M., Mobashery, S., and Fridman, R. (2005). Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res. 65, 3523-3526.
27. Lah, T.T., Duran Alonso, M.B., and van Noorden, C.J. (2006). Antiprotease therapy in cancer: Hot or not? Expert Opin. Biol. Ther. 6, 257-279.
28. Martin, M.D., and Matrisian, L.M. (2007). The other side of MMPs: Protective roles in tumor progression. Cancer Metastasis Rev. 26, 717-724.
29. Praus, M., Wauterickx, K., Collen, D., and Gerard, R.D. (1999). Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther. 6, 227-236.
30. Ramaswamy, S., Ross, K.N., Lander, E.S., and Golub, T.R. (2003). A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33, 49-54.
31. Rauvala, M., Puistola, U., and Turpeenniemi-Hujanen, T. (2005). Gelatinases and their tissue inhibitors in ovarian tumors: TIMP-1 is a predictive as well as a prognostic factor. Gynecol. Oncol. 99, 656-663.
32. Reuning, U., Magdolen, V., Wilhelm, O., Fischer, K., Lutz, V., Graeff, H., and Schmitt, M. (1998). Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis [review]. Int. J. Oncol. 13, 893-906.
33. Schmitt, M., Wilhelm, O.G., Reuning, U., Krüger, A., Harbeck, N., Lengyel, E., Graeff, H., Gansbacher, B., Kessler, H., Bürgle, M., Stürzebecher, J., Sperl, S., and Magdolen, V. (2000). The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis Proteolysis 14, 114-132.
34. Schweinitz, A., Steinmetzer, T., Banke, I.J., Arlt, M.J., Stürzebecher, A., Schuster, O., Geissler, A., Giersiefen, H., Zeslawska, E., Jacob, U., Krüger, A., and Stürzebecher, J. (2004). Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J. Biol. Chem. 279, 33613-33622.
35. Vasiljeva, O., Papazoglou, A., Krüger, A., Brodoefel, H., Korovin, M., Deussing, J., Augustin, N., Nielsen, B.S., Almholt, K., Bogyo, M., Peters, C., and Reinheckel, T. (2006). Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 66, 5242-5250.
36. Visse, R., and Nagase, H. (2003). Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ. Res. 92, 827-839.
37. Wu, Z.S., Wu, Q., Yang, J.H., Wang, H.Q., Ding, X.D., Yang, F., and Xu, X.C. (2008). Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int. J. Cancer 122, 2050-2056.
38. Ylisirnio, S., Hoyhtya, M., and Turpeenniemi-Hujanen, T. (2000). Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer: TIMP-1 as a prognostic marker. Anticancer Res. 20, 1311-1316.
39. Yukawa, N., Yoshikawa, T., Akaike, M., Sugimasa, Y., Rino, Y., Masuda, M., and Imada, T. (2007). Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology 72, 205-208.